Jun 1, 2020
Dr. Mark Erlander, CEO, Cardiff Oncology identifies the unmet needs of those suffering from metastatic colorectal cancer who have the oncogene KRAS mutation that hyper-drives the tumor growth. Mark talks about the company's investigational drug, onvansertib that is being evaluated in metastatic colorectal cancer (mCRC), acute myeloid leukemia (AML), and metastatic castrate-resistant prostate cancer (mCRPC). Onvansertib is a first-in-class, third-generation, oral and highly-selective inhibitor of PLK1, an enzyme that is over-expressed in most types of cancers. Onvansertib works synergistically in combination with approved chemotherapies and targeted therapeutics.
#onvansertib #cancer #oncology #drugdevelopment #colorectalcancer #KRAS